Mather Group’s Cellebrite CLBT Stock Holding History

Mather Group’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-270	Closed	-$2.99K	–	1802
2024 Q2	$2.99K	Buy	+270	New	+$3.02K	﹤0.01%	1773

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Mather Group's CLBT Position: Q3 2024 in Review

Mather Group sold out of Cellebrite (CLBT) in Q3 2024, closing a stake of 270 shares — an estimated $2.99K sold.

Mather Group first reported a position in CLBT in Q2 2024 and held it in 1 quarter. The position peaked at $2.99K in Q2 2024. 164 funds tracked by Wall St. Rank hold CLBT as of Q3 2024.

Mather Group reported no remaining Cellebrite position as of Q3 2024 after selling out during the quarter.
Mather Group sold 270 Cellebrite shares in Q3 2024, an estimated $2.99K.
Mather Group first reported a position in Cellebrite in Q2 2024 and held it in 1 quarter.
Mather Group's Cellebrite position peaked at $2.99K in Q2 2024.
164 funds tracked by Wall St. Rank held Cellebrite as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.